Our Pipeline

We aim to address key drivers of cancer and turn cold tumors hot, with a diverse range of mode of actions and smart combinations.

LATEST DEVELOPMENT PHASE (AS OF APRIL 2026)

Download Pipeline PDF

FOCUS AREA

• DEDIFFERENTIATED LIPOSARCOMA
• BILIARY TRACT CANCER
• GLIOBLASTOMA
• NON-SMALL CELL LUNG CANCER
• SMALL CELL LUNG CANCER
• COLORECTAL CANCER
• GASTROINTESTINAL CANCER
• NEUROENDOCRINE CARCINOMA
• SOLID TUMORS

DEVELOPMENT STAGE

• IN PREPARATION
• PHASE I
• PHASE II
• PHASE III

TARGET

• CELL DEATH/APOPTOSIS
• ERBB SIGNALING
• PROTEIN::PROTEIN INTERACTION
• ADAPTIVE IMMUNITY
• CANCER VACCINES
• CHECKPOINT INHIBITION
• INNATE IMMUNITY

Pipeline Phases

• Phase III: NSCLC
• Phase 1b: NSCLC
• Phase 1a: Solid tumors
• Phase II: HER2+ mBC and mGEAC (Part 2)
• Phase I: HER2+ mBC and mGEAC (Part 1)
• Phase II: Pan-tumor

zongertinib

Phase III: NSCLC

Phase 1b: NSCLC

Phase 1a: Solid tumors

Phase II: HER2+ mBC and mGEAC (Part 2)

Phase I: HER2+ mBC and mGEAC (Part 1)

Phase II: Pan-tumor

DLL3/CD3 T-cell engager obrixtamig

Phase II: epNEC

Phase I: ES-SCLC

Phase I: ES-SCLC/other NECs expressing DLL3

B7-H6/CD3 T-cell engager

Phase I: Solid tumors

ezabenlimab

Phase I: Solid tumors

CD137 FAP bispecific agonist antibody

Phase I: Solid tumors

SIRPα antagonist

Phase I: Solid tumors

VSV-GP oncolytic virus

Phase I: Solid tumors

2nd generation STING agonist

Phase I: Solid tumors

KRAS multi-inhibitor

Phase I: Solid tumors

Combination Therapies

• B7-H6/CD3 T-cell engager + ezabenlimab
• CD137 FAP bispecific agonist antibody + ezabenlimab
• SIRPα antagonist (BI 770371) + ezabenlimab
• VSV-GP + ezabenlimab
• 2nd generation STING agonist + ezabenlimab
• DLL3/CD3 T-Cell engager + ezabenlimab

Exploratory Cohort

These compounds are investigational agents and have not been approved for use by any regulatory authority. Their efficacy and safety have not been established.

References

1. ClinicalTrials.gov. NCT05218499. https://clinicaltrials.gov/study/NCT05218499
2. ClinicalTrials.gov. NCT05512377. https://clinicaltrials.gov/study/NCT05512377
3. ClinicalTrials.gov. NCT04886804. https://clinicaltrials.gov/study/NCT04886804
4. ClinicalTrials.gov. NCT04429087. https://clinicaltrials.gov/study/NCT04429087
5. ClinicalTrials.gov. NCT05882058. https://clinicaltrials.gov/study/NCT05882058
6. ClinicalTrials.gov. NCT04752215. https://clinicaltrials.gov/study/NCT04752215
7. ClinicalTrials.gov. NCT03697304. https://clinicaltrials.gov/study/NCT03697304
8. ClinicalTrials.gov. NCT02952248. https://clinicaltrials.gov/study/NCT02952248
9. ClinicalTrials.gov. NCT04958239. https://clinicaltrials.gov/study/NCT04958239
10. ClinicalTrials.gov. NCT03990233. https://clinicaltrials.gov/study/NCT03990233
11. ClinicalTrials.gov. NCT05249426. https://clinicaltrials.gov/study/NCT05249426
12. ClinicalTrials.gov. NCT05068102. https://clinicaltrials.gov/study/NCT05068102
13. ClinicalTrials.gov. NCT05327946. https://clinicaltrials.gov/study/NCT05327946
14. ClinicalTrials.gov. NCT05155332. https://clinicaltrials.gov/study/NCT05155332
15. ClinicalTrials.gov. NCT05839600. https://clinicaltrials.gov/study/NCT05839600
16. ClinicalTrials.gov. NCT05471856. https://clinicaltrials.gov/study/NCT05471856
17. ClinicalTrials.gov. NCT06056024. https://clinicaltrials.gov/study/NCT06056024
18. ClinicalTrials.gov. NCT03964233. https://clinicaltrials.gov/study/NCT03964233

BTC, biliary tract cancer; CD, cluster of differentiation; CRC, colorectal cancer; DLL3, Delta-like 3; epNEC, extra-pulmonary neuroendocrine carcinomas; ES-SCLC, extensive stage small-cell lung cancer; FAP, fibroblast activation protein; GBM, glioblastoma; GEJ, gastroesophageal junction; GI, gastrointestinal; GP, glycoprotein; HER2, human epidermal growth factor receptor 2; NEC, neuroendocrine carcinoma; NSCLC, non-small-cell lung cancer; SIRPα, signal-regulatory protein alpha; STING, small molecule agonist of the stimulator of interferon genes; TKI, tyrosine kinase inhibitor; VSV, vesicular stomatitis virus.